Cyclin A1 appears to be a highly suitable antigen in patients with EOC for targeted T-cell therapy because of its selectively high expression in the vast majority of high-grade ovarian cancers irrespective of clinical stage. The gene discussed is CCNA1; the disease is ovarian cancer.